The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Jupiter Endovascular has treated the first two patients in the SPIRARE I study, utilising its Vertex pulmonary embolectomy ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...